WAVE Life Sciences Ltd.
WVE
$6.59
$0.0450.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -89.04% | 1,191.04% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -89.04% | 1,191.04% | |||
| Cost of Revenue | -9.01% | 8.37% | |||
| Gross Profit | -180.42% | 180.01% | |||
| SG&A Expenses | 13.76% | 7.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.96% | 8.08% | |||
| Operating Income | -316.85% | 135.93% | |||
| Income Before Tax | -260.25% | 147.35% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -260.25% | 147.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -260.25% | 147.35% | |||
| EBIT | -316.85% | 135.93% | |||
| EBITDA | -304.95% | 137.92% | |||
| EPS Basic | -259.25% | 138.86% | |||
| Normalized Basic EPS | -259.28% | 138.86% | |||
| EPS Diluted | -268.16% | 136.49% | |||
| Normalized Diluted EPS | -269.93% | 136.42% | |||
| Average Basic Shares Outstanding | 0.64% | 21.82% | |||
| Average Diluted Shares Outstanding | -5.67% | 29.97% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||